References

phkinetica

Фармакокинетика и Фармакодинамика

Pharmacokinetics and Pharmacodynamics

2587-78362686-8830

ООО «Издательство ОКИ»

10.37489/2587-7836-2025-4-9-16

phkinetica-480

Research Article

МЕХАНИЗМ ДЕЙСТВИЯ

MECHANISM OF ACTION

Вовлечённость нейротрофинов в патогенез болезни Паркинсона

Involvement of neurotrophins in the pathogenesis of Parkinson's disease

https://orcid.org/0000-0003-3278-8915

Поварнина

П. Ю.

Povarnina

P. Yu.

Поварнина Полина Юрьевна — к. б. н., в. н. с. лаборатории пептидных биорегуляторов отдела химии лекарственных средств

Москва

Polina Yu. Povarnina — PhD, Cand. Sci. (Biol.), Leading Research Scientist of the Laboratory of Peptide Bioregulators of the Medicinal Chemistry Department

Moscow

povarnina-pyu@academpharm.ru

https://orcid.org/0000-0002-5185-4474

Гудашева

Т. А.

Gudasheva

T. A.

Гудашева Татьяна Александровна — д. б. н., профессор, член-корреспондент РАН, руководитель отдела химии лекарственных средств ФГБНУ «ФИЦ оригинальных и перспективных биомедицинских и фармацевтических технологий»

Москва

Tatiana A. Gudasheva — PhD, Dr. Sci. (Biology), Professor, RAS corresponding member, Head of medicinal chemistry department Federal Research Center for Innovators and Emerging Biomedical and Pharmaceutical Technologies

Moscow

gudasheva_ta@academpharm.ru

https://orcid.org/0009-0004-3584-3742

Дорофеев

В. Л.

Dorofeev

V. L.

Дорофеев Владимир Львович — д. фарм. н., профессор, и. о. генерального директора ФГБНУ «ФИЦ оригинальных и перспективных биомедицинских и фармацевтических технологий»

Москва

Vladimir L. Dorofeev — PhD, Dr. Sci. (Pharm), Professor, Acting General Director of Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies

Moscow

dorofeev_vl@academpharm.ru

ФГБНУ «ФИЦ оригинальных и перспективных биомедицинских и фармацевтических технологий»РоссияFederal research center for innovator and emerging biomedical and pharmaceutical technologiesRussian Federation

2025

30122025

04916

2026

Поварнина П.Ю., Гудашева Т.А., Дорофеев В.Л.

Povarnina P.Y., Gudasheva T.A., Dorofeev V.L.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.pharmacokinetica.ru/jour/article/view/480

Болезнь Паркинсона — второе по распространённости нейродегенеративное заболевание, связанное с прогрессирующей гибелью дофаминер гических нейронов чёрной субстанции. К моменту появления первых симптомов заболевания и соответственно возможности его диагностики происходит потеря 50–60 % дофаминергических нейронов чёрной субстанции и снижение уровня дофамина в стриатуме на 70–80 %. Современная фармакотерапия болезни Паркинсона всё ещё остаётся преимущественно симптоматической и направлена на компенсацию дефицита дофамина в ЦНС. В связи с этим актуально создание новых противопаркинсонических средств, способных как замедлять нейродегенерацию, так и стимулировать нейрогенез. Белки семейства нейротрофинов являются эндогенными нейропротекторами, а также активируют репаративные процессы в повреждённой нервной ткани. В настоящем обзоре суммированы данные литературы о связи нейротрофинов с патогенезом болезни Паркинсона и об их антипаркинсоническом потенциале.

Parkinson's disease is the second most common neurodegenerative disease, associated with the progressive loss of dopaminergic neurons in the substantia nigra. By the time the ﬁrst symptoms of the disease appear and, accordingly, the possibility of its diagnosis arises, 50–60 % of dopaminergic neurons in the substantia nigra are lost, and the dopamine level in the striatum decreases by 70–80 %. Modern pharmacotherapy for Parkinson's disease is still predominantly symptomatic and aimed at compensating for the dopamine deﬁciency in the CNS. In this regard, the development of new antiparkinsonian drugs capable of both slowing down neurodegeneration and stimulating neurogenesis is relevant. Proteins of the neurotrophin family are endogenous neuroprotectors and also activate reparative processes in damaged nervous tissue. This review consolidates current literature on the role of neurotrophins in the pathogenesis of Parkinson's disease and evaluates their potential as a therapeutic strategy.

нейротрофиныNGFBDNFNT-3NT-4болезнь Паркинсона

neurotrophinsNGFBDNFNT-3NT-4Parkinson's disease

Работа выполнена в рамках государственного задания Министерства науки и высшего образования Российской Федерации (FGFG-2025-0008).

This work was conducted under the government contract of the Ministry of Science and Higher Education of the Russian Federation (FGFG-2025-0008).

References1

Luo Y, Qiao L, Li M, et al. Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Front Aging Neurosci. 2025 Jan 10;16:1498756. doi: 10.3389/fnagi.2024.1498756.

Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015 Aug 29;386(9996):896-912. doi: 10.1016/S0140-6736(14)61393-3.

Stefani A, Pierantozzi M, Cardarelli S, et al. Neurotrophins as Therapeutic Agents for Parkinson's Disease; New Chances From Focused Ultrasound? Front Neurosci. 2022 Mar 25;16:846681. doi: 10.3389/fnins.2022.846681.

Chmielarz P, Saarma M. Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies. Pharmacol Rep. 2020 Oct;72(5):1195-1217. doi: 10.1007/s43440-020-00120-3.

Watanabe H, Dijkstra JM, Nagatsu T. Parkinson's Disease: Cells Succumbing to Lifelong Dopamine-Related Oxidative Stress and Other Bioenergetic Challenges. Int J Mol Sci. 2024 Feb 7;25(4):2009. doi: 10.3390/ijms25042009.

Гусев Е.И., Блохин В.Е., Вартанов С.А., и др. Разработка ранней диагностики болезни Паркинсона и комплексный экономический анализ эффекта от ее внедрения. Журнал неврологии и психиатрии им. С.С. Корсакова. 2021;121(1):9-20. doi: 10.17116/jnevro20211210119.

Gusev EI, Blokhin VE, Vartanov SA, et al. Development of early diagnosis of Parkinson’s disease and comprehensive economic analysis of the effect of its implementation. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(1):9-20. (In Russ.). doi: 10.17116/jnevro20211210119.

Skaper SD. Neurotrophic Factors: An Overview. Methods Mol Biol. 2018;1727:1-17. doi: 10.1007/978-1-4939-7571-6_1.

Ateaque S, Merkouris S, Barde YA. Neurotrophin signalling in the human nervous system. Front Mol Neurosci. 2023 Jul 4;16:1225373. doi: 10.3389/fnmol.2023.1225373.

Bothwell M. NGF, BDNF, NT3, and NT4. Handb Exp Pharmacol. 2014;220:3-15. doi: 10.1007/978-3-642-45106-5_1.

Hyman C, Hofer M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 1991 Mar 21;350(6315):230-2. doi: 10.1038/350230a0.

Beck KD, Knüsel B, Hefti F. The nature of the trophic action of brain-derived neurotrophic factor, des(1-3)-insulin-like growth factor-1, and basic fibroblast growth factor on mesencephalic dopaminergic neurons developing in culture. Neuroscience. 1993 Feb;52(4):855-66. doi: 10.1016/0306-4522(93)90534-m.

Ma B, Savas JN, Chao MV, Tanese N. Quantitative analysis of BDNF/ TrkB protein and mRNA in cortical and striatal neurons using α-tubulin as a normalization factor. Cytometry A. 2012 Aug;81(8):704-17. doi: 10.1002/cyto.a.22073.

Hernández-Echeagaray E. Neurotrophin-3 modulates synaptic transmission. Vitam Horm. 2020;114:71-89. doi: 10.1016/bs.vh.2020.04.008.

Numan S, Seroogy KB. Expression of trkB and trkC mRNAs by adult midbrain dopamine neurons: a double-label in situ hybridization study. J Comp Neurol. 1999 Jan 18;403(3):295-308. doi: 10.1002/(sici)1096-9861(19990118)403:33.0.co;2-l.

Baquet ZC, Gorski JA, Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci. 2004 Apr 28;24(17):4250-8. doi: 10.1523/JNEUROSCI.3920-03.2004.

Altar CA, Cai N, Bliven T, et al. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 1997 Oct 23;389(6653):856-60. doi: 10.1038/39885.

Baquet ZC, Bickford PC, Jones KR. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci. 2005 Jun 29;25(26):6251-9. doi: 10.1523/JNEUROSCI.4601-04.2005.

Feng L, Wang CY, Jiang H, et al. Differential effects of GDNF and BDNF on cultured ventral mesencephalic neurons. Brain Res Mol Brain Res. 1999 Mar 20;66(1-2):62-70. doi: 10.1016/s0169-328x(99)00015-7.

Hyman C, Juhasz M, Jackson C, et al. Overlapping and distinct actions of the neurotrophins BDNF, NT-3, and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J Neurosci. 1994 Jan;14(1):335-47. doi: 10.1523/JNEUROSCI.14-01-00335.1994.

Holtzman DM, Kilbridge J, Li Y, et al. TrkA expression in the CNS: evidence for the existence of several novel NGF-responsive CNS neurons. J Neurosci. 1995 Feb;15(2):1567-76. doi: 10.1523/JNEUROSCI.15-02-01567.1995.

Hatanaka H. Nerve growth factor-mediated stimulation of tyrosine hydroxylase activity in a clonal rat pheochromocytoma cell line. Brain Res. 1981 Oct 19;222(2):225-33. doi: 10.1016/0006-8993(81)91029-5.

Greene LA, Seeley PJ, Rukenstein A, et al. Rapid activation of tyrosine hydroxylase in response to nerve growth factor. J Neurochem. 1984 Jun;42(6):1728-34. doi: 10.1111/j.1471-4159.1984.tb12764.x.

Su Z, Jiang X, Wang C, et al. Differential effects of nerve growth factor on expression of dopamine 2 receptor subtypes in GH3 rat pituitary tumor cells. Endocrine. 2012 Dec;42(3):670-5. doi: 10.1007/s12020-012-9715-y.

Blöchl A, Sirrenberg C. Neurotrophins stimulate the release of dopamine from rat mesencephalic neurons via Trk and p75Lntr receptors. J Biol Chem. 1996 Aug 30;271(35):21100-7. doi: 10.1074/jbc.271.35.21100.

Tirassa P. The nerve growth factor administrated as eye drops activates mature and precursor cells in subventricular zone of adult rats. Arch Ital Biol. 2011 Jun;149(2):205-13. doi: 10.4449/aib.v149i1.1359.

Geng X, Zou Y, Li J, et al. BDNF alleviates Parkinson's disease by promoting STAT3 phosphorylation and regulating neuronal autophagy. Cell Tissue Res. 2023 Sep;393(3):455-470. doi: 10.1007/s00441-023-03806-1.

Chang E, Wang J. Brain-derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson's disease. Brain Behav. 2021 Aug;11(8):e2251. doi: 10.1002/brb3.2251.

Somoza R, Juri C, Baes M, et al. Intranigral transplantation of epigenetically induced BDNF-secreting human mesenchymal stem cells: implications for cell-based therapies in Parkinson's disease. Biol Blood Marrow Transplant. 2010 Nov;16(11):1530-40. doi: 10.1016/j.bbmt.2010.06.006.

Levivier M, Przedborski S, Bencsics C, Kang UJ. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci. 1995 Dec;15(12):7810-20. doi: 10.1523/JNEUROSCI.15-12-07810.1995.

Chaturvedi RK, Shukla S, Seth K, Agrawal AK. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease. Neurosci Lett. 2006 May 1;398(1-2):44-9. doi: 10.1016/j.neulet.2005.12.042.

Курахмаева К.Б., Воронина Т.А., Капица И.Г., и др. Антипаркинсоническое действие фактора роста нервов, сорбированного на полибутилцианакрилатных наночастицах, покрыты полисорбатом-80. Бюллетень экспериментальной биологии и медицины. 2008;145(2):221-4. doi: 10.1007/s10517-008-0065-y.

Kurakhmaeva KB, Voronina TA, Kapica IG, et al. Antiparkinsonian effect of nerve growth factor adsorbed on polybutylcyanoacrylate nanoparticles coated with polysorbate-80. Bull Exp Biol Med. 2008;145(2):259-62. (In Russ.). doi: 10.1007/s10517-008-0065-y.

Gu S, Huang H, Bi J, Yao Y, Wen T. Combined treatment of neurotrophin-3 gene and neural stem cells is ameliorative to behavior recovery of Parkinson's disease rat model. Brain Res. 2009 Feb 27;1257:1-9. doi: 10.1016/j.brainres.2008.12.016.

Altar CA, Boylan CB, Fritsche M, et al. Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions. J Neurochem. 1994 Sep;63(3):1021-32. doi: 10.1046/j.1471-4159.1994.63031021.x.

Omar NA, Kumar J, Teoh SL. Neuroprotective effects of Neurotrophin-3 in MPTP-induced zebrafish Parkinson's disease model. Front Pharmacol. 2023 Nov 28;14:1307447. doi: 10.3389/fphar.2023.1307447.

Haque NS, Hlavin ML, Fawcett JW, Dunnett SB. The neurotrophin NT4/5, but not NT3, enhances the efficacy of nigral grafts in a rat model of Parkinson's disease. Brain Res. 1996 Mar 11;712(1):45-52. doi: 10.1016/0006-8993(95)01427-6.

Howells DW, Porritt MJ, Wong JY, et al. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol. 2000 Nov;166(1):127-35. doi: 10.1006/exnr.2000.7483.

Hernández-Vara J, Sáez-Francàs N, Lorenzo-Bosquet C, et al. BDNF levels and nigrostriatal degeneration in "drug naïve" Parkinson's disease patients. An "in vivo" study using I-123-FP-CIT SPECT. Parkinsonism Relat Disord. 2020 Sep;78:31-35. doi: 10.1016/j.parkreldis.2020.06.037.

Wang Y, Liu H, Zhang BS, et al. Low BDNF is associated with cognitive impairments in patients with Parkinson's disease. Parkinsonism Relat Disord. 2016 Aug;29:66-71. doi: 10.1016/j.parkreldis.2016.05.023.

Scalzo P, Kümmer A, Bretas TL, et al. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. J Neurol. 2010 Apr;257(4):540-5. doi: 10.1007/s00415-009-5357-2.

Huang Y, Yun W, Zhang M, et al. Serum concentration and clinical significance of brain-derived neurotrophic factor in patients with Parkinson's disease or essential tremor. J Int Med Res. 2018 Apr;46(4):1477-1485. doi: 10.1177/0300060517748843.

Kaagman DGM, van Wegen EEH, Cignetti N, et al. Effects and Mechanisms of Exercise on Brain-Derived Neurotrophic Factor (BDNF) Levels and Clinical Outcomes in People with Parkinson's Disease: A Systematic Review and Meta-Analysis. Brain Sci. 2024 Feb 21;14(3):194. doi: 10.3390/brainsci14030194.

Cholewa J, Nowacka-Chmielewska M, Gorzkowska A, et al. Changes in proBDNF and Mature BDNF Levels After Medium-Intensity Functional Motor Rehabilitation Program in Patients with Parkinson's Disease. Int J Mol Sci. 2025 Apr 11;26(8):3616. doi: 10.3390/ijms26083616.

Lorigados Pedre L, Pavón Fuentes N, Alvarez González L, et al. Nerve growth factor levels in Parkinson disease and experimental parkinsonian rats. Brain Res. 2002 Oct 11;952(1):122-7. doi: 10.1016/s0006-8993(02)03222-5.

Mufson EJ, Presley LN, Higgins GA, Kordower JH. Alterations in Nerve Growth Factor Receptor Containing Neurons in Parkinson’s Disease. In: Nagatsu T, Fisher A, Yoshida M, (eds). Basic, Clinical, and Therapeutic Aspects of Alzheimer’s and Parkinson’s Diseases. Advances in Behavioral Biology. Vol 38A. Springer, Boston, MA. 1990. p.619-20. doi: 10.1007/978-1-4684-5844-2_125.

Weissmiller AM, Wu C. Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl Neurodegener. 2012 Jul 26;1(1):14. doi: 10.1186/2047-9158-1-14.

Luo D, Shi Y, Wang J, et al. 7,8-dihydroxyflavone protects 6-OHDA and MPTP induced dopaminergic neurons degeneration through activation of TrkB in rodents. Neurosci Lett. 2016 May 4;620:43-9. doi: 10.1016/j.neulet.2016.03.042.

Massaquoi MS, Liguore WA, Churchill MJ, et al. Gait Deficits and Loss of Striatal Tyrosine Hydroxlase/Trk-B are Restored Following 7,8-Dihydroxyflavone Treatment in a Progressive MPTP Mouse Model of Parkinson's Disease. Neuroscience. 2020 May 1;433:53-71. doi: 10.1016/j.neuroscience.2020.02.046.

Kang SS, Wu Z, Liu X, et al. Treating Parkinson's Disease via Activation of BDNF/TrkB Signaling Pathways and Inhibition of Delta-Secretase. Neurotherapeutics. 2022 Jul;19(4):1283-1297. doi: 10.1007/s13311-022-01248-1.

Антипова Т.А., Гудашева Т.А., Середенин С.Б. Новые низкомолекулярные миметики фактора роста нервов. Доклады Академии Наук. 2010;434(4):549-552. doi: 10.1134/S160767291005011X. EDN: NBSZVL

Antipova TA, Gudasheva TA, Seredenin SB. Novel low-molecular-weight mimetics of the nerve growth factor. Doklady Biochemistry and Biophysics. 2010;434(4):549–552. (In Russ.). doi: 10.1134/S160767291005011X. EDN: NBSZVL

Антипова Т.А., Гудашева Т.А., Середенин С.Б. Исследование in vitro нейропротективных свойств нового оригинального миметика фактора роста нервов ГК-2. Бюллетень экспериментальной биологии и медицины. 2010;150(11):537-540. doi: 10.1007/s10517-011-1202-6.

Antipova TA, Gudasheva TA, Seredenin SB. In vitro study of neuroprotective properties of GK-2, a new original nerve growth factor mimetic. Bull Exp Biol Med. 2011 Mar;150(5):607-9. (In Russ.). doi: 10.1007/s10517-011-1202-6.

Поварнина П.Ю., Гудашева Т.А., Воронцова О.Н., и др. Антипаркинсонические свойства дипептидного миметика фактора роста нервов ГК-2 в экспериментах in vivo. Бюллетень экспериментальной биологии и медицины. 2011;151(6):634-37. doi: 10.1007/s10517-011-1417-6.

Povarnina PY, Gudasheva TA, Vorontsova ON, et al. Antiparkinsonian properties of a nerve growth factor dipeptide mimetic GK-2 in in vivo experiments. Bull Exp Biol Med. 2011 Oct;151(6):690-3. (In Russ.). doi: 10.1007/s10517-011-1417-6.

von Bohlen Und Halbach O, Klausch M. The Neurotrophin System in the Postnatal Brain-An Introduction. Biology (Basel). 2024 Jul 24;13(8):558. doi: 10.3390/biology13080558.

The authors declare that there are no conflicts of interest present.